SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:DiVA.org:kth-303538"
 

Search: onr:"swepub:oai:DiVA.org:kth-303538" > Development of humo...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Development of humoral and cellular immunological memory against SARS-CoV-2 despite B cell depleting treatment in multiple sclerosis

Högelin, Klara Asplund (author)
Karolinska Institutet
Ruffin, Nicolas (author)
Karolinska Institutet
Pin, Elisa (author)
KTH,Affinitets-proteomik,Science for Life Laboratory, SciLifeLab
show more...
Månberg, Anna, 1985- (author)
KTH,Science for Life Laboratory, SciLifeLab,Affinitets-proteomik
Hober, Sophia, Professor, 1965- (author)
KTH,Science for Life Laboratory, SciLifeLab,Proteinteknologi
Gafvelin, Guro (author)
Karolinska Inst, Ctr Mol Med L8 02, Dept Clin Neurosci, Therapeut Immune Design Unit, S-17176 Stockholm, Sweden.
Grönlund, Hans (author)
Karolinska Institutet
Nilsson, Peter (author)
KTH,Science for Life Laboratory, SciLifeLab,Affinitets-proteomik
Khademi, Mohsen (author)
Karolinska Institutet
Olsson, Tomas (author)
Karolinska Institutet
Piehl, Fredrik (author)
Karolinska Institutet
Al Nimer, Faiez (author)
Karolinska Institutet
show less...
 (creator_code:org_t)
Elsevier BV, 2021
2021
English.
In: iScience. - : Elsevier BV. - 2589-0042. ; 24:9
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • B cell depleting therapies (BCDTs) are widely used as immunomodulating agents for autoimmune diseases such as multiple sclerosis. Their possible impact on development of immunity to severe acute respiratory syndrome virus-2 (SARS-CoV-2) has raised concerns with the coronavirus disease 2019 (COVID-19) pandemic. We here evaluated the frequency of COVID-19-like symptoms and determined immunological responses in participants of an observational trial comprising several multiple sclerosis disease modulatory drugs (COMBAT-MS; NCT03193866) and in eleven patients after vaccination, with a focus on BCDT. Almost all seropositive and 17.9% of seronegative patients on BCDT, enriched for a history of COVID-19-like symptoms, developed anti-SARS-CoV-2 T cell memory, and T cells displayed functional similarity to controls producing IFN-gamma and TNF. Following vaccination, vaccine-specific humoral memory was impaired, while all patients developed a specific T cell response. These results indicate that BCDTs do not abrogate SARS-CoV-2 cellular memory and provide a possible explanation as to why the majority of patients on BCDTs recover from COVID-19.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Medicinska och farmaceutiska grundvetenskaper -- Cell- och molekylärbiologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Basic Medicine -- Cell and Molecular Biology (hsv//eng)

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

  • iScience (Search for host publication in LIBRIS)

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view